Michael Rabinowitz - 03 Jan 2023 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Role: Chief Commercial Officer
Signature: /s/ Michael Rabinowitz
Issuer symbol: ORMP
Transactions as of: 03 Jan 2023
Net transactions value: -$167,195
Form type: 4
Filing time: 04 Jan 2023, 06:24:13 UTC
Previous filing: 01 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ORMP	Common Stock	Sale	$18,544	-1,425	-1%	$13.01	138,043	03 Jan 2023	Direct	F1
transaction	ORMP	Common Stock	Sale	$148,651	-11,900	-8.6%	$12.49	126,143	03 Jan 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $13.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $13.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.